deCODE launches new phase of drug test Skip to content

deCODE launches new phase of drug test

By Iceland Review

DeCODE genetics announced yesterday a new phase in an ongoing trial for DGO31, a drug designed to reduce risk of heart attack.

Phase III of the trial for the DG031drug will enrol 3400 patients with a history of recent heart attack and is being conducted under the US Food and Drug Administration. According to a deCODE press release, the trial will administer two daily doses of DGO31, focusing on African American heart patients who carry an at-risk variant of a gene decode has linked to the risk of heart attack.

In 2005, deCODE identified a gene variant that, while indicating a moderate increase in risk of heart attack in people of European ancestry, indicates a 250 percent increase in the risk in African Americans.

DeCODE is an Icelandic company which specializes in applying genetic studies to developing drugs for common diseases. Nearly half of men and a third of women who reach the age of 40 will suffer a heart attack in their lifetime, according to statistics released by deCODE.

Sign up for our weekly newsletter

Get news from Iceland, photos, and in-depth stories delivered to your inbox every week!

* indicates required

Subscribe to Iceland Review

In-depth stories and high-quality photography showcasing life in Iceland!